Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation

  • Authors:
    • Zhongliang Ma
    • Jinlian Song
    • Simin Liu
    • Linlin Han
    • Yangping Chen
    • Yaqiu Wang
    • Chundong Yu
    • Lin Hou
  • View Affiliations

  • Published online on: September 16, 2016     https://doi.org/10.3892/ol.2016.5147
  • Pages: 4021-4026
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chromodomain helicase DNA binding protein 5 (CHD5) has been identified as a tumor suppressor in mouse models. Downregulation of CHD5 gene expression is frequently observed in breast cancer cells and tissues. This may be explained by deletions or other mutations; however, alternative mechanisms require investigation. Therefore, the present study evaluated whether CHD5 aberrant methylation has a role in primary breast tumors. A total of 389 patients with primary breast cancer (including 252 paraffin‑embedded specimens and 137 fresh‑frozen samples) were enrolled in the present study. In the current study, reverse transcription‑polymerase chain reaction (RT‑PCR) and nested‑methylation‑specific PCR were used to analyze the mRNA expression and promoter methylation of CHD5 genes in a large cohort of breast cancer patients, and to investigate their associations with the clinicopathological features of tumors. CHD5 expression was significantly suppressed in breast cancer tissues compared with normal breast tissues when analyzed by RT‑PCR. Furthermore, DNA methylation of CHD5 was more prevalent in breast tumors than in normal tissues. CHD5 mRNA levels correlated with the degree of CHD5 methylation in breast cancer tissues. Clinicopathological correlation analysis revealed that CHD5 promoter methylation was associated with estrogen receptor and progesterone receptor status. Thus, downregulation of CHD5, mediated by abnormal methylation, may contribute to the development and progression of breast cancer.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ma Z, Song J, Liu S, Han L, Chen Y, Wang Y, Yu C and Hou L: Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation. Oncol Lett 12: 4021-4026, 2016.
APA
Ma, Z., Song, J., Liu, S., Han, L., Chen, Y., Wang, Y. ... Hou, L. (2016). Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation. Oncology Letters, 12, 4021-4026. https://doi.org/10.3892/ol.2016.5147
MLA
Ma, Z., Song, J., Liu, S., Han, L., Chen, Y., Wang, Y., Yu, C., Hou, L."Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation". Oncology Letters 12.5 (2016): 4021-4026.
Chicago
Ma, Z., Song, J., Liu, S., Han, L., Chen, Y., Wang, Y., Yu, C., Hou, L."Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation". Oncology Letters 12, no. 5 (2016): 4021-4026. https://doi.org/10.3892/ol.2016.5147